AMCP To FDA: Tread Carefully On Biosimilar Naming As Policy Will Drive Pharmacists' Decisions

As FDA gears up to decide on the first biosimilar as early as next week, the Academy of Managed Care Pharmacy says the agency needs to tread carefully on naming because new survey results suggest a move to give biosimilars distinct names could result in dispensing pharmacists being less comfortable substituting interchangeable biosimilars with their reference products. Nearly 75 percent of pharmacists said they would be confident or very confident substituting interchangeable biosimilars with their reference products if they share...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.